Smoking cessation lowers the risk of cancer and other serious health problems. Some products contain nicotine as an active ingredient and others do not. Counseling, behavior therapy, medicines, and nicotine-containing products, such as nicotine patches, gum, lozenges, inhalers, and nasal sprays, may be used to help a person quit smoking. They are regulated through the FDA’s Center for Drug Evaluation and Research, which ensures that the products are safe and effective and that their benefits outweigh any known associated risks.
Johnson and Johnson Services, Inc., and Pfizer Inc. – Notable Market Players in Smoking Cessation Aids Market
Market leaders operating in the market have undertaken various organic growth strategies in the Smoking cessation aids market. The Smoking cessation aids market majorly consists of the players Pfizer Inc., GlaxoSmithKline plc., Dr. Reddy’s Laboratories, Johnson and Johnson Services, Inc., Cipla Inc., Perrigo Company plc, Bausch Health Companies Inc., Glenmark, NJOY, Juul Labs among others. The companies have been implementing various strategies that have helped the growth of the company and in turn have brought about various changes in the market. The companies have utilized organic strategies such as launches, expansion, and product approvals. Moreover, the companies have utilized inorganic strategies including mergers & acquisitions, partnership, and collaborations.
Below is the list of the growth strategies done by the players operating in the Smoking cessation aids market:
| Year | News |
| Jul-20 | Dr Reddy’s Laboratories launched of over-the-counter Nicotine Polacrilex lozenges in the American market in the strengths of 2 mg and 4 mg.. |
| Sept-19 | An independent expert panel to the U.S. Food and Drug Administration recommended approval of GlaxoSmithKline Plc’s over-the-counter nicotine oral spray which aims to help smokers quit their addiction. |
| Nov-17 | Glenmark Pharmaceuticals Ltd, launched Kwitz, a medically approved nicotine replacement therapy in India. Kwitz Nicotine gum will be available in two variants. |
| Nov-20 | Perrigo Company plc completed its the fourth year of its “Quitting is Better” campaign in partnership with the American Cancer Society (ACS). |
| Nov-19 | Witi, partnered with Perrigo to license Witi’s patent-pending hardware and software IP in development of a new, inventive smoking cessation product. The companies will develop an Electronic Nicotine Delivery System that if successful, would be submitted for approval by the US Food and Drug Administration (FDA) and other international regulatory agencies |
